Literature DB >> 15710875

Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats.

Giulia D'Intino1, Michela Paradisi, Mercedes Fernandez, Alessandro Giuliani, Luigi Aloe, Luciana Giardino, Laura Calzà.   

Abstract

Clinical symptoms in multiple sclerosis include cognitive dysfunction. Difficulties in learning and remembering new information represent the most common cognitive deficit and are associated with a general and progressive brain pathology. Possible pathogenetic mechanisms for neuronal damage such as neuroprotective strategies are under active investigation also in experimental allergic encephalomyelitis, the most widely used experimental model for multiple sclerosis. In this paper we demonstrate that a selective deficit in learning and memory performance, as investigated by the Morris water maze test, is a consistent feature in rat encephalomyelitis, which correlates with a decline in choline acetyltransferase activity and nerve growth factor mRNA level in cerebral cortex, hippocampus, and basal forebrain. Treatment aimed to restore acetylcholine content through chronic administration of selective acetylcholinesterase inhibitors (rivastigmine and donepezil) restores cognitive performance, choline acetyltransferase activity, and nerve growth factor mRNA expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710875      PMCID: PMC548798          DOI: 10.1073/pnas.0500073102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  58 in total

1.  A disturbance of late myelination as a trigger for Alzheimer's disease.

Authors:  Francine M Benes
Journal:  Neurobiol Aging       Date:  2004-01       Impact factor: 4.673

Review 2.  The possible role of myelin destruction as a precipitating event in Alzheimer's disease.

Authors:  Mark Noble
Journal:  Neurobiol Aging       Date:  2004-01       Impact factor: 4.673

Review 3.  The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease.

Authors:  Paul S Aisen
Journal:  Lancet Neurol       Date:  2002-09       Impact factor: 44.182

4.  The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease.

Authors:  G L Wenk; K McGann; B Hauss-Wegrzyniak; S Rosi
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 5.  Cognitive dysfunction in multiple sclerosis: a review of recent developments.

Authors:  Julie A Bobholz; Stephen M Rao
Journal:  Curr Opin Neurol       Date:  2003-06       Impact factor: 5.710

Review 6.  Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2004-01       Impact factor: 4.673

7.  Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis.

Authors:  M B Sättler; D Merkler; K Maier; C Stadelmann; H Ehrenreich; M Bähr; R Diem
Journal:  Cell Death Differ       Date:  2004-12       Impact factor: 15.828

Review 8.  Inflammatory processes in Alzheimer's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-08       Impact factor: 5.067

Review 9.  Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease.

Authors:  Shivanand P Lad; Kenneth E Neet; Elliott J Mufson
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2003-10

10.  Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine.

Authors:  Allyson M M Parry; Richard B Scott; Jacqueline Palace; Stephen Smith; Paul M Matthews
Journal:  Brain       Date:  2003-09-04       Impact factor: 13.501

View more
  22 in total

1.  Neuroscience in Africa.

Authors:  Susan J van Rensburg; Brian Harvey
Journal:  Metab Brain Dis       Date:  2006-09       Impact factor: 3.584

2.  Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus.

Authors:  Henri Autio; Kert Mätlik; Tomi Rantamäki; Lothar Lindemann; Marius C Hoener; Moses Chao; Urmas Arumäe; Eero Castrén
Journal:  Neuropharmacology       Date:  2011-07-30       Impact factor: 5.250

Review 3.  Inflammation induced neurological handicap processes in multiple sclerosis: new insights from preclinical studies.

Authors:  Klaus G Petry; Bruno Brochet; Vincent Dousset; Jean Rodolphe Vignes; Claudine Boiziau
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

Review 4.  Cognitive deficits in experimental autoimmune encephalomyelitis: neuroinflammation and synaptic degeneration.

Authors:  G Mandolesi; G Grasselli; G Musumeci; Diego Centonze
Journal:  Neurol Sci       Date:  2010-11       Impact factor: 3.307

Review 5.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

6.  Short-latency afferent inhibition predicts verbal memory performance in patients with multiple sclerosis.

Authors:  Laura Cucurachi; Paolo Immovilli; Franco Granella; Giovanni Pavesi; Luigi Cattaneo
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

7.  Pathophysiological aspects of the formation of neurological deficit in multiple sclerosis.

Authors:  A V Peresedova; E V Baidina; O V Trifonova; O S Korepina; V V Gnezditskii; M V Krotenkova; R N Konovalov; L A Chernikova; N S Alekseeva; I M Kirichenko; O Yu Rebrova; I A Zavalishin
Journal:  Neurosci Behav Physiol       Date:  2009-01

Review 8.  Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?

Authors:  Christopher Christodoulou; William S MacAllister; Nancy A McLinskey; Lauren B Krupp
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Hippocampal neurodegeneration in experimental autoimmune encephalomyelitis (EAE): potential role of inflammation activated myeloperoxidase.

Authors:  Mir Sajad; Jamil Zargan; Raman Chawla; Sadiq Umar; Mir Sadaqat; Haider A Khan
Journal:  Mol Cell Biochem       Date:  2009-03-20       Impact factor: 3.396

10.  Donepezil treatment restores the ability of estradiol to enhance cognitive performance in aged rats: evidence for the cholinergic basis of the critical period hypothesis.

Authors:  R B Gibbs; R Mauk; D Nelson; D A Johnson
Journal:  Horm Behav       Date:  2009-03-20       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.